Actively Recruiting
A Real-world Study on the Efficacy and Safety of Adebrelimab in the Treatment of Advanced-stage Small Cell Lung Cancer
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-02-25
500
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
S
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor
S
Shanghai Pulmonary Hospital, Shanghai, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of adebrelimab, a PD-L1 inhibitor, in treating patients with advanced small cell lung cancer (SCLC) under real-world conditions. This observational study focuses on understanding how adebrelimab works in daily practice, particularly monitoring the incidence of serious immune-related side effects. The study also aims to observe overall survival, progression-free survival, response rates, and disease control in these patients, while considering factors like brain or liver metastases and biomarkers. Participants receiving adebrelimab will be monitored for safety starting from the beginning of their treatment and continuing until 90 days after their last dose. The study tracks various outcomes for up to 12 months from enrollment, including survival rates and treatment responses. It also examines immune cell changes in the blood over three months. This approach helps gather valuable information about adebrelimab's performance in different patient groups, including elderly individuals and those with other health conditions. During the study, patients' safety is closely observed through monitoring immune-related adverse events and other side effects. Researchers will collect data on survival and disease progression at regular intervals over one year. Blood samples will be taken to assess immune cells before and after treatment. The study's total duration for each patient varies but includes ongoing safety checks for three months post-treatment. This comprehensive follow-up aims to provide a clear picture of adebrelimab's impact in routine clinical use.
CONDITIONS
Brief Title
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed extensive-stage small cell lung cancer
- Age 18 years or older
- Eligible for or currently receiving adebrelimab treatment as determined by the investigator
You will not qualify if you...
- Currently receiving other immune-modulating drugs or therapies
- Participating in other interventional clinical studies
- Having other concurrent malignancies
- Missing key study-related data required for the trial assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants receive adebrelimab treatment and are monitored for efficacy and safety.
Duration - 90 days after the last dose
Participants are monitored for safety with immune-related adverse events and other adverse events for 90 days after the last dose of adebrelimab.
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, China, 201620
Actively Recruiting
Research Team
Q
Qingnan Zhao, PhD
Q
Qian Xue, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here